Suppression of the dynamic interaction of estrogen receptor with chromatin is critical for therapeutic ligands to repress ER-mediated transcription activities

Mathilda Jing Chow1,2,3, Jingyi Peng1,2,3, Yingying Su1,2,3, Damu Tang1,2,3

1Department of Medicine, McMaster University, 2The Research Institute of St Joe’s Hamilton, 3Urological Cancer Center for Research and Innovation (UCCRI), St. Joseph’s Hospital, Hamilton, Ontario, Canada

Introduction

Breast cancer (BC) is the second leading cause of cancer deaths in women with annual new cases and fatality of 1.7 million and 500,000 respectively (1). Estrogen receptor-positive (ER+) BCs constitute 75% of the cases, and contribute to approximately 50% BC fatality (1). ERα plays critical roles in BC progression in part via transactivating Myc, cyclin D1, vascular endothelial growth factor, and other important oncogenic factors (2,3). Targeting ERα remains the standard of care in ER+ BCs; endocrine therapy (ET) is likely the most successful targeted cancer therapies. Adjuvant tamoxifen decreases mortality and recurrence by 31% and 50% respectively (4,5). The current toolbox of ET includes estrogen biosynthesis inhibitors (aromatase inhibitors, AIs) and therapeutic ligands; the latter consists of selective estrogen modulators (SERMs, like tamoxifen) and fulvestrant, a selective estrogen down-regulator (SERD). Although ET is clearly beneficial and with multiple options, ER+ BCs remains a major cause of BC mortality because of resistance. While resistance to ET (ETR) is mediated by complex mechanisms, persistent ER signaling under ET is a major attributor to the resistance; loss of ERα was reported in 17–28% of relapse BCs (6-8). The contributions of ERα in relapse BCs underlies multiple rounds of ET using alternative endocrine treatment. For instance, approximately 20% of relapse ER+ BCs following tamoxifen treatment are sensitive to AI and fulvestrant (9,10) and approximately 40% of recurrent ER+ BCs have mutations in ERα (11). Collectively, evidence supports an important role of persistent ERα function in ETR development.

The above situation also outlines a clear need to more effectively target ERα. Tamoxifen possesses partial agonist activities. In comparison, fulvestrant is a pure antagonist and thus a more potent antiestrogen, which is attributable to its action of inducing ERα degradation. However, the clinical application of fulvestrant is limited because of its poor solubility and intramuscular route of administration (12,13). This status underlies the current interest in developing new SERDs with improved pharmacokinetic properties for oral administration. Several of these SERDs have been developed and entered clinical trials, including GDC-0810 (multicenter phase Ia/Ii: NCT01823835), AZD9496 (phase I: NCT02248090; an open-label randomized multicenter trial: NCT03236974), RAD1901 (Elacetrant; phase III: NCT03778931; EudraCT 2018-002990-24), GDC-0927 (NCT02316509), and others.

To develop effective antiestrogen ligands, a deep understanding of the mechanisms utilized by the current therapeutic ligands will provide a framework to guide this effort. ERα has been extensively investigated (the number of articles listed in PubMed under “estrogen receptor alpha”: n=20,816) following the cloning of human ERα from MCF7 cells in 1986 (14). ERα is a member of the nuclear receptor superfamily; it consists of 6 domains A-F with domain C...
and E as the DNA binding and the ligand-binding domain (LBD) respectively (Figure 1); the two activation functions are AF1 (domains A and B) and AF2 within the E domain (Figure 1) (16). The LBD motif is composed of 12 helices; reposition of the transactivation helix or helix 12 (h12) upon ligand binding defines ERα transcription activity. Binding of estradiol (E2) to LBD induces h12 to fold back, allowing h12 together with h3-h5 to form the co-activator binding groove (CBG) for co-activator recruitment (17). Binding of tamoxifen repositions h12 to the CBG space via association with h3-h4, preventing CBG formation (11,18). This antagonistic action can be reversed with mutations of two residues, L543A and L544A, in h12 of mouse ERα (mERα); this reverses tamoxifen and fulvestrant into agonists (16). E380, S463, and those residues from C530 to A546 have been selected for systematic mutagenesis by Guan et al. (15). Knowledge together with the different efficacies of tamoxifen (partial agonist) and fulvestrant (full agonist) as antiestrogens suggests complex mechanisms underlying the antagonizing actions of antiestrogens.

To gain insights on these mechanisms, Guan et al. have reported an elegant and comprehensive study on a set of therapeutic ligands: tamoxifen, fulvestrant, some newly developed SERDs with better pharmacokinetic properties (GDC-0810, AZD9496, and GDC-0927), and GNE-274 which shares structural similarities with GDC-0927 without causing ERα degradation (15); the composition of this set of ligands contains ERα degraders (fulvestrant, GDC-0810, AZD9496, and GDC-0927) and non-ERα degraders (tamoxifen and GNE-274).

**Associations of therapeutic ligands’ antiestrogen activities with their abilities to induce ERα degradation**

Guan et al. started their research by examining the impact of tamoxifen, GNE-274, GDC-0810, AZD9496, GDC-
0927, and fulvestrant on the proliferation of 6 ERα-positive and HER2-negative lines MCF7, MB-134 (MDA-MB-134-VI), HCC1500, EFM-19, CAMA-1, and T47D in vitro. Fulvestrant and GDC-0927 are more potent ERα degraders and inhibitors of cell proliferation; in MCF7, MB-134, and EFM-19 cells, ERα degraders (fulvestrant, GDC-0810, AZD9496, and GDC-0927) achieved higher levels of maximal inhibition on cell proliferation than tamoxifen and GNE-274. In vivo, GDC-0927 is more potent to inhibit E2-dependent growth of patient-derived ERα xenograft (PDX) HCl-013 and HCI-011 compared to GDC-0810, consistent with the former inducing ERα degradation more effectively. Nonetheless, both antiestrogens displayed comparable inhibition of MCF7 xenograft growth (15). Additionally, RNA-seq analyses of gene expression of 8 ERα lines (the above 6 lines plus two HER2+ lines BT-474 and MDA-MB-340/MB-330) revealed the antagonistic activities (suppression of ERα-regulated gene expression) in the order of fulvestrant > GDC-0927 > GDC-0810 > tamoxifen and GNE-274. In both HCI-013 and HCI-011 PDXs, GDC-0927 exhibits superiority to GDC-0810 in suppression of ERα-regulated gene expression. These observations support a positive correlation between the level of antagonistic activities of these therapeutic ligands and their ability to induce ERα degradation.

### Differential impacts on chromatin accessibility by ERα-liganded with agonists or antagonists

The comparable binding of ERα-E2 and ERα-antagonist to chromatin raises the issue whether both ERα-ligand complexes affect chromatin configuration similarly. To address this, the authors performed another comprehensive research: Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) to profile open chromatin regions. In MCF7 cells treated for 45 minutes with E2, tamoxifen, GNE-274, GDC-0927, or fulvestrant, the number of

### Table 1: Effects of ligands on ERα binding to chromatin

<table>
<thead>
<tr>
<th>Ligand</th>
<th>ChIP site (n)</th>
<th>Site (n) with accessibility altered</th>
<th>Accessible site/ChIP sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>E2</td>
<td>16114</td>
<td>1,808</td>
<td>1139/10304</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>16287</td>
<td>568</td>
<td>444/10639</td>
</tr>
<tr>
<td>GNE-274</td>
<td>22517</td>
<td>594</td>
<td>373/14182</td>
</tr>
<tr>
<td>GDC-0927</td>
<td>-12,000</td>
<td>38</td>
<td>18/9004</td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>-12000</td>
<td>1</td>
<td>0/9899</td>
</tr>
</tbody>
</table>

i, both accessible sites and ChIP sites are those with significantly changes over control (fold >2; FDR <0.05); ii, vehicle control sites n=4,413 are not excluded.

© Biotarget. All rights reserved. Biotarget 2020;4:1 | http://dx.doi.org/10.21037/biotarget.2020.01.01
sites with chromatin accessibility altered was 1,808, 568, 594, 38, or 1 with predominant changes for increases in accessibility (Table 1) (15). Furthermore, among the ERα binding sites detected by ChIP in MCF7 cells treated with E2, tamoxifen, GNE-274, GDC-0927, or fulvestrant, sites with significantly altered accessibility (fold change >2; FDR <0.05) are 1139/10304 (accessible site/ChIP sites), 444/10639, 373/14182, 18/9004, or 0/9899 (Table 1) (15).

These altered accessible sites are enriched for ERE motif, and are associated with transcription activity at least for some ERα target genes (ADORA1, PGR, RET, AGR3, and FKBP4) in MCF7 cells treated with E2, tamoxifen, GNE-274, GDC-0810, GDC-0927, or fulvestrant (15). Taken together, data demonstrate that the inaccessibility of chromatin contributes to the antagonistic potential of individual therapeutic ligands examined. These observations are in accordance with the current knowledge that binding of antagonists prevents co-activator association (18).

Impairment of the dynamics of ERα-chromatin association by fulvestrant and GDC-0927

Narrowing down the differences between ERα-agonist and ERα-antagonist to their unique association with chromatin, the authors examined their dynamic association with chromatin, which is an emerging feature of transcription factors (23). MCF7 cells were engineered to stably express mNeon-tagged ERα; the ectopic protein performs similar as the endogenous counterpart in terms of ligand-induced degradation. These cells were treated with individual ligands for 45 minutes prior to photobleaching, followed by monitoring the recovery of fluorescence signals within 60 seconds. The recovery is in a rapid kinetics with a final recovery of 70–80% in cells treated with tamoxifen, GNE-274, GDC-0810, or AZD9496 in comparison to a much slower and less recovery (60–65%) in cell treated with either GDC-0927 or fulvestrant (15). Guan et al. concluded that immobilization of ERα by fulvestrant and GDC-0927 is a causation of ER degradation.

To show ERα mobility being relevant to ER turn over and its transcription activity, Guan et al. aimed to find ERα mutants that reverse antagonists into agonists with concurrent improvements of ERα mobility. The mutations of mERα (L543A, L544A) (16) and hERα (L540Q) reverse antagonists into agonists (11,20); mutations of Y537S, D538G, L536, S463P, and E380Q were detected in recurrent ERα BCs (Figure 1); and h12 plays critical roles in forming AF2 (11). With this knowledge, the authors have performed a systemic mutagenesis in 20 residues, including E380, S463, R503, and amino acids 530–546 (Figure 1). Along with the re-discovery of Y537S, a set of mutants were identified from mutations in K531F, V534N, and h12 residues: L539D (similar to L543A in mERα), M543K, and L544D/E (Figure 1) (15). Fulvestrant acts as an agonist to V534N, L539D, and M534K (Figure 1) without inducing their degradation and compromising their mobility (15). Other therapeutic ligands (tamoxifen, GNE-274, and GDC-0927) also activate L539D (Figure 1). The agonist activities of tamoxifen, GNE-274, GDC-0927, and fulvestrant towards these mutants were not derived from AF2, as L539D does not clearly recruit co-activator peptides (n=154) in the presence of E2, tamoxifen, GNE-274, GDC-0810, GDC-0927, or fulvestrant. However, inactivation mutation of AF1 in hERα (L539D) prevents all therapeutic ligands (tamoxifen, GNE-274, GDC-0927, and fulvestrant) from inducing L539D activation, indicating transcription activities being attributable to AF1 (15).

Perspectives

By taking multiple systematic approaches (RNA-seq, ChIP-seq, ATAC-seq, and mutational screen), this research reveals that the antiestrogen functions of SERDs are not attributable to their ability of inducing ERα degradation, neither to preventing ERα from binding to ERE sites. These observations are in accordance with (I) the formation of the same dimers by binding of either agonists or antagonist and (II) ERα dimers binding DNA (17). Nonetheless, antagonist-ligated ERα is unable to make these ERE motifs accessible for transcription activities. This knowledge may provide a framework to develop more effective ERα antagonists, which may not focus on their ability to cause ERα degradation. In this regard, it will be interesting to investigate H3B-5942 actions of antagonist. H3B-5942 is a newly developed selective estrogen receptor covalent antagonist (SERCA) which causes ERα degradation through covalent targeting C530 (24). Nonetheless, the conclusions of this article require further investigations, as both ChIP-seq and ATAC-seq were essentially carried out in a single MCF7 cell line.

While the ERα mobility studies coupled with mutagenesis screening support an association of ERα immobilization with fulvestrant- and GDC-0927-derived ERα degradation, whether immobilization contributes to ERα turn over and suppression of ERα transcription regulation remains unclear. In the mNeon-tagged ERα
stable lines, GDC-0810 displayed a comparable efficiency in inducing ERα degradation to GDC-0927 without clear immobilization of ERα (Figure 1). In parental MCF7 cells, GDC-0927 does not apparently lead to ERα degradation but does so in mNeon-tagged ERα stable line. Furthermore, tamoxifen, GNE-274, GDC-0810, and AZD9496 are all largely antagonists without apparently affecting ERα motility. Lastly, ICI164384 was reported to relocate h12 to a position without association with other LBD domains in ERβ, which may destabilize ERβ (25). The possibility for a similar mechanism in fulvestrant-liganded ERα should be considered. Clearly, the necessity of ERα mobility needs to be further elucidated, as well as the immobilization effects of fulvestrant and GDC-0927. For instance, how will binding of fulvestrant or GDC-0927 to the loss of function mutant (AF1mut.L539D) affect the ERα mobility?

Mutation of L511R in mouse ERα (L543A, L544A) renders tamoxifen and fulvestrant to be incapable of inducing mERα dimerization and activation (16); the residue is conserved (L507) in hERα. It will be interesting to examine the performance of hERα (L507; L539D) with the set of therapeutic ligands studied by Guan et al. As formation of dimers via a ligand binding sets the motion of ERα binding to DNA, can the mERα (L511R, L543A, L544A) structural information or hERα (L507; L539D) be explored for developing antagonists to prevent ERα dimerization?

Acknowledgments

Funding: This work is supported by a grant from Canadian Cancer Society (grant #: 319412) to D Tang.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

21. Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 2011;82:122-30.

doi: 10.21037/biotarget.2020.01.01

Cite this article as: Chow MJ, Peng J, Su Y, Tang D. Suppression of the dynamic interaction of estrogen receptor with chromatin is critical for therapeutic ligands to repress ER-mediated transcription activities. Biotarget 2020;4:1.